Pre-made Docaravimab benchmark antibody ( Whole mAb (Mouse), anti-Rabies Virus Strain ERA GP Ectodomain Epitope G-III therapeutic antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Docaravimab biosimilar, Whole mAb (Mouse): Anti-Rabies Virus Strain ERA GP Ectodomain Epitope G-III therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-150-1mg	1mg	3090
GMP-Bios-ab-150-10mg	10mg	Inquiry
GMP-Bios-ab-150-100mg	100mg	Inquiry
GMP-Bios-ab-150-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Docaravimab biosimilar, Whole mAb (Mouse): Anti-Rabies Virus Strain ERA GP Ectodomain Epitope G-III therapeutic antibody
INN Name	Docaravimab
Target	Rabies Virus Strain ERA GP Ectodomain Epitope G-III
Format	Whole mAb (Mouse)
Derivation
Species Reactivity	Human
CH1 Isotype	IgG2b
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Approved
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2019
Year Recommended	2020
Companies	Candila Healthcare
Conditions Approved	Rabies
Conditions Active	na
Conditions Discontinued	na
Development Tech	na